HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Receive this page by email each issue: [Sign up for eTOCs] Other Issues: Contents: Volume 179, Meeting Abstracts, April 1, 2009   [Index by Author]  American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California Sunday, May 17 Monday, May 18 Tuesday, May 19 Wednesday, May 20 Find articles in this issue containing these words: [Search ALL Issues] Sunday, May 17 A13. INSIGHTS IN COPD PATHOGENESIS A14. ADVANCES IN THE DIAGNOSIS AND TREATMENT OF LATENT TUBERCULOSIS INFECTION A15. PULMONARY INFECTIONS: MODULATING HOST DEFENSES A16. ASTHMA MANAGEMENT/MONITORING COPD A17. TREATMENT OF PAH A18. PULMONARY REHABILITATION: ADDING MUSCLE TO THERAPY FOR PATIENTS WITH RESPIRATORY DISEASE A19. IMAGING THE DISTAL LUNG: ADVANCES IN TECHNIQUE AND APPLICATION A20. PHYSIOLOGICAL RESPONSES TO INTERMITTENT HYPOXIA A21. PSYCHOSOCIAL AND BEHAVIORAL FACTORS IN LUNG DISEASE A22. CLINICAL TOPICS IN LUNG CANCER A23. ILD: OUTCOMES AND SELECTED CLINICAL ISSUES A24. MECHANISMS OF SEPSIS A25. EVIDENCE FROM HUMAN STUDIES ON THE CARDIOVASCULAR EFFECTS OF AIR POLLUTION A26. NEW DATA REGARDING CYSTIC FIBROSIS A27. GENETIC AND ACQUIRED CILIA DISEASE A28. CELLULAR AND TISSUE RESPONSE TO MECHANICAL STRESS A29. SLEEP-DISORDERED BREATHING: EPIDEMIOLOGY, DIAGNOSIS AND MANAGEMENT A30. ASTHMA: CLINICAL STUDIES A31. EFFECTS OF CIGARETTE SMOKE ON INFLAMMATORY CELL BIOLOGY A32. GRANULOCYTE AND MACROPHAGE BIOLOGY A33. MEASUREMENT FACTORS AFFECTING NON-INVASIVE ASSESSMENT OF AIRWAY INFLAMMATION A34. AIRWAY INFLAMMATION A35. EFFECTIVENESS AND ORGANIZATION OF HEALTHCARE IN PULMONARY/CRITICAL CARE MEDICINE A36. ADULT CYSTIC FIBROSIS A37. COPD COMORBIDITIES A38. COPD: DIAGNOSIS & EVALUATION A39. COPD EXACERBATIONS A40. COPD: FUNCTIONAL ASSESSMENT A41. CLINICAL TRIALS IN ICU A42. MONITORING IN THE ICU A43. STRATEGIES FOR IDENTIFYING HARMFUL AGENTS, REDUCING EXPOSURES, AND PREVENTING DISEASE A44. OCCUPATIONAL AIRWAY AND SKIN DISEASES A45. GENETIC BASIS FOR ENVIRONMENTAL AND OCCUPATIONAL RESPIRATORY DISEASES A46. TREATMENT OF MYCOBACTERIAL INFECTIONS A47. COMMUNITY ACQUIRED PNEUMONIA AND HEALTHCARE ASSOCIATED PNEUMONIA A48. VENTILATOR-ASSOCIATED AND NOSOCOMIAL PNEUMONIA A49. SLEEP AND CONTROL OF BREATHING A50. CYSTIC FIBROSIS BASIC, CLINICAL AND TRANSLATIONAL STUDIES A51. EXPERIMENTAL MODELS OF PULMONARY HYPERTENSION A52. VASCULAR REMODELING AND ANGIOGENESIS A53. VASCULAR SMOOTH MUSCLE CELLS A54. ALVEOLAR GENE EXPRESSION REGULATION: TRANSCRIPTION AND GROWTH FACTORS A55. OMICS AND INFORMATICS A56. SIGNAL TRANSDUCTION: CELL SURFACE TO NUCLEUS A57. RESIDENT CELL PLASTICITY AND SURVIVAL A58. LUNG STEM AND PROGENITOR CELLS A59. STEM CELL AND TISSUE ENGINEERING THERAPEUTICS A60. INSIGHT FROM ANIMAL MODELS OF EMPHYSEMA II A61. EXERCISE IN HEALTH AND DISEASE A62. THE CYTOSKELETON AND CELL CONTRACTILITY A63. ALVEOLAR STRUCTURE AND PATHOLOGY A64. GAS EXCHANGE, HIGH ALTITUDE AND HYPOXIA A65. SLEEP MEDICINE FROM LUNG DISORDERS TO PHARMACOLOGY A66. EPIDEMIOLOGY AND DIAGNOSIS OF SLEEP-DISORDERED BREATHING A91. MEASURING AND IMPROVING THE QUALITY OF CARE IN LUNG DISEASE A92. FIVE RANDOMIZED CLINICAL TRIALS WITH EDITORIAL DISCUSSION A93. NEW INSIGHTS INTO THE PATHOGENESIS OF INTERSTITIAL LUNG DISEASE A94. ASTHMA AS A SYSTEMIC DISEASE: THE ROLE OF COMORBIDITIES A95. MICROBES AND ORGANIC DUSTS AT WORK A96. TUBERCULOSIS: ASSESSING TRANSMISSION AND RISK A97. BEST IN PEDIATRICS A98. INSIGHT FROM ANIMAL MODELS OF EMPHYSEMA I A101. MOUSE MODELS OF ALLERGIC INFLAMMATION: MECHANISMS A102. NEW FINDINGS IN SARCOIDOSIS A103. NEW INSIGHTS INTO HIV-RELATED PULMONARY COMPLICATIONS A104. ISSUES IN COPD/RESPIRATORY FAILURE A105. MECHANICAL VENTILATION: MODES, WEANING AND MONITORING A106. ROLE OF INFLAMMATION IN PULMONARY VASCULAR REMODELING AND INJURY A107. ADDING TO THE SCIENCE OF PULMONARY REHABILITATION A108. THE AIRWAY EPITHELIUM: THE ENVIRONMENT, INJURY, AND REPAIR A109. PATHOPHYSIOLOGY OF THE HYPERRESPONSIVE AIRWAY I Monday, May 18 B13. ADVANCES IN RESPIRATORY GENETICS B14. PEDIATRIC ASTHMA: OPPORTUNITIES AND CHALLENGES TO IMPROVING OUTCOMES B15. COPD PHARMACOTHERAPY B16. COST EFFECTIVENESS OF CRITICAL CARE AND ORGANIZATION B17. NOVEL CELL SIGNALING MECHANISMS IN PULMONARY VASCULAR CELLS: POTENTIAL THERAPEUTIC TARGETS B18. microRNAs IN THE LUNG: BIT PLAYER OR LEADING ROLE? B19. NOVEL MECHANISMS IN ACUTE LUNG INJURY B21. AIRWAY INFLAMMATION: NEW INFORMATION ABOUT MEDIATORS AND BIOMARKERS B22. IMPROVING LONG-TERM OUTCOMES AFTER LUNG TRANSPLANTATION: INSIGHTS FROM CLINICAL, TRANSLATIONAL AND BASIC RESEARCH B23. THE MECHANISMS AND HEALTH EFFECTS OF OZONE B24. DIAGNOSING RESPIRATORY TRACT INFECTIONS: IN SEARCH OF THE HOLY GRAIL B25. SMOKING AND SMOKING CESSATION B26. PULMONARY DEVELOPMENTAL BIOLOGY B27. FROM ALPHA TO OMEGA: ASSESSMENT AND OUTCOMES IN PULMONARY HYPERTENSION B28. LUNG CANCER BIOMARKERS OF RISK B29. TRANSLATIONAL INVESTIGATION INTO MECHANISMS OF LUNG FIBROSIS B30. GENETICS OF AIRWAY DISEASES I B31. ASTHMA THERAPEUTICS -- STUDIES IN HUMANS B32. MUCOSAL IMMUNITY AND AIRWAY EPITHELIA B33. IMMUNOLOGY/INFLAMMATION B34. CLINICAL ISSUES IN COPD B35. COPD: NON-PHARMACOLOGICAL TREATMENT B36. COPD OUTCOMES B37. COPD PATHOGENESIS B38. CLINICAL ASPECTS OF ILD B39. COPD: GENETICS B40. ILD -- PATHOGENESIS B41. PULMONARY ALVEOLAR PROTEINOSIS B42. NONINVASIVE VENTILATION B43. MECHANICAL VENTILATION: APPLICATIONS AND WEANING B44. ORGANIZATION AND GUIDELINES IN THE ICU B45. ANIMAL AND CELL MODELS FOR THE CARDIOVASCULAR EFFECTS OF AIR POLLUTION B46. AIR POLLUTION MECHANISMS AND TOXICOLOGY B47. SARCOIDOSIS AND BERYLLIUM DISEASE: MECHANISMS AND EPIDEMIOLOGY B48. DIAGNOSIS OF MYCOBACTERIAL DISEASE B49. NON-CYSTIC FIBROSIS BRONCHIECTASIS: EVALUATION AND MANAGEMENT B50. LUNG HOST DEFENSES TO INFECTION AND HOST CELL PATHOGEN INTERACTION B51. PATHOGENIC MECHANISMS OF INFECTIONS B52. DEVELOPMENTAL BIOLOGY B53. ACUTE PULMONARY EMBOLISM: DIAGNOSIS, PREVENTION, AND TREATMENT B54. CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION B55. PULMONARY HYPERTENSION -- CLINICAL B56. PULMONARY EDEMA: CLINICAL B57. ENGINEERING THE LUNG: BIOMECHANICS OF THE LUNG CIRCULATION B58. PULMONARY REHABILITATION B59. PULMONARY FIBROSIS: ANIMAL MODELS B60. PULMONARY FIBROSIS: THE FIBROBLAST B61. PROTEASE DISEASE MECHANISMS B62. ALPHA-1 ANTITRYPSIN: MOLECULAR, EPIDEMIOLOGICAL, AND CLINICAL FEATURES IN 2009 B63. IMAGING: EVOLVING TECHNOLOGIES AND RELATION TO PATHOLOGY B64. CELLULAR AND MOLECULAR ASPECTS OF ACUTE LUNG INJURY B65. SLEEP-DISORDERED BREATHING: MANAGEMENT AND OUTCOMES B66. THE UPPER AIRWAY: CONTROL OF FUNCTION AND PATHOPHYSIOLOGY B67. SLEEP DISORDERED BREATHING AND CARDIOVASCULAR MORBIDITY: CLINICAL ASPECTS B91. THE YIN AND YANG OF LUNG INJURY: NEW INSIGHTS INTO MECHANISMS OF PROGESSION AND RESOLUTION B92. NEW TREATMENT APPROACHES FOR ASTHMA AND ALLERGY B93. NEW ADVANCES IN MECHANICAL VENTILATION B94. GENE ENVIRONMENT INTERACTION INVOLVING OXIDATIVE STRESS AND INFLAMMATORY PATHWAYS IN ASTHMA AND COPD B95. ASSESSING EXPOSURES FROM OUTER SPACE TO THE LUNG B96. NEW DATA REGARDING UNCOMMON PEDIATRIC LUNG DISEASES B97. MESENCHYMAL STEM CELLS IN THE LUNG: RECRUITMENT, RETENTION, AND PERFORMANCE B98. CONTROL OF VENTILATION: WAKEFULNESS TO SLEEP, ANIMALS TO HUMANS B101. GRANULOCYTE ACTIVATION AND EXECUTION OF EFFECTOR FUNCTIONS IN THE LUNG B102. IMMUNE MECHANISMS IN THE AIRWAY AND RESPONSE TO INJURY AND INFECTION B103. PRACTICE VARIATION, PATIENT BEHAVIOR AND DIFFERENCES IN DISEASE SUSCEPTABILITY AS SOURCES OF HEALTH OUTCOME DISPARITIES B104. COPD BIOMARKERS: WHAT CAN THEY TELL US B105. MECHANICAL VENTILATION: MODES -- WEANING AND MONITORING B106. MECHANISMS OF VENTILATOR ASSOCIATED LUNG INJURY B107. FUNCTIONAL STATUS AND ACTIVITY IN PATIENTS WITH CHRONIC RESPIRATORY DISEASE B108. ACUTE LUNG INJURY: FROM GENES, PATHWAYS AND MODELS TO PATIENTS B109. AIRWAY SMOOTH MUSCLE PHENOTYPE AND FUNCTION Tuesday, May 19 C13. MECHANISMS OF DISEASE IN HUMAN ASTHMA C14. MESOTHELIOMA -- BENCH TO BEDSIDE C15. ILD AND CONNECTIVE TISSUE DISORDERS I C16. INNATE LUNG DEFENSE IN COPD C17. SMOKING CESSATION C18. RISK FACTORS FOR CHILDHOOD ASTHMA C19. BEYOND THE CODE: EPIGENETICS IN DIFFERENTIATION AND DISEASE C20. ENDOTHELIAL DYSFUNCTION AND BEYOND IN SLEEP DISORDERED BREATHING C21. PATHS TO LUNG INJURY AND REPAIR C22. COPD COMORBIDITIES -- CARDIOVASCULAR DISEASE, DEPRESSION, OSTEOPOROSIS C23. ILD: MANAGEMENT AND COMORBIDITIES C24. EVALUATING DISEASE CONTROL AND QUALITY OF LIFE IN ASTHMA AND COPD C25. DIAGNOSIS AND TREATMENT OF MYCOBACTERIAL INFECTIONS C26. BASIC AND CLINICAL STUDIES ON BRONCHOPULMONARY DYSPLASIA C27. RIGHT VENTRICULAR FUNCTION AND EXERCISE C28. EXTRACELLULAR STRESS REGULATORY MECHANISMS AND DISEASE C29. SKELETAL MUSCLE FUNCTION AND DYSFUNCTION C30. INFLAMMATORY AND IMMUNOLOGICAL MODELS OF ASTHMA C31. MECHANISMS OF INFLAMMATION IN THE AIRWAY C32. IMMUNE CELLULAR NETWORK IN LUNG INFLAMMATION C33. PATIENT-REPORTED OUTCOMES AND MEASURES: NEW TOOLS AND UNDERSTANDING EXISTING ONES C34. COPD PHENOTYPES C35. NEW FINDINGS IN LAM C36. LUNG CANCER: CLINICAL ASPECTS I C37. LUNG CANCER: CLINICAL ASPECTS II C38. LUNG CANCER EPIDEMIOLOGY C39. LUNG REDUCTION C40. DIFFUSE LUNG DISEASES C41. NEW FINDINGS IN PULMONARY FUNCTION C42. LUNG CANCER CLINICAL TREATMENT C43. PLEURAL DISEASE I -- DIAGNOSTIC ISSUES C44. PLEURAL DISEASE II -- CHEST TUBES, MANAGEMENT, PATHOPHYSIOLOGY C45. ILD AND CONNECTIVE TISSUE DISORDERS II C46. THORACIC SURGERY C47. COPD EPIDEMIOLOGY C48. COPD: PHARMACOLOGICAL TREATMENT BETA AGONIST C49. COPD: PHARMACOLOGICAL TREATMENT LAMA C50. COPD: PHARMACOLOGICAL TREATMENT INHALED CORTICOSTEROIDS C51. COPD: PHARMACOLOGICAL TREATMENT C52. COPD: PHARMACOLOGICAL TREATMENT NEW AGENTS C53. LUNG TRANSPLANTATION: DONOR SELECTION AND RECIPIENT MANAGEMENT C54. ALI/ARDS: DIAGNOSIS AND OUTCOMES C55. MECHANICAL VENTILATION: PHYSIOLOGY C56. SEPSIS: FROM BENCH TO THE BEDSIDE C57. INDOOR AND OUTDOOR AIR POLLUTION: EXPOSURES AND EPIDEMIOLOGY C58. ASTHMA EPIDEMIOLOGY: ETIOLOGY AND OUTCOMES C59. EPIDEMIOLOGY OF TUBERCULOSIS C60. CLINICAL AND EPIDEMIOLOGICAL STUDIES C61. PEDIATRIC ASTHMA C62. PEDIATRIC PULMONARY DIAGNOSTICS C63. DETERMINANTS OF PULMONARY HYPERTENSION OUTCOMES C64. DIAGNOSIS OF PULMONARY HYPERTENSION: HEMODYNAMICS AND BIOMARKERS C65. PULMONARY HYPERTENSION ASSOCIATED WITH LUNG DISEASES OR OTHER ILLNESSES: PATHOGENESIS, DIAGNOSIS, AND CLINICAL OUTCOMES C66. TRANSPORT AND SECRETION C67. AIRWAY EPITHELIUM RESPONSE TO INJURY C68. ALVEOLAR EPITHELIUM C69. LUNG CANCER MECHANISMS OF INITIATION AND PROGRESSION C70. LUNG CANCER MECHANISMS OF TREATMENT RESPONSE C71. MOLECULAR MECHANISM AND PHYSIOLOGY OF AEROSOL AND NANOPARTICLES C72. AIRWAY REMODELING: FUNCTIONAL CONSEQUENCES C73. ASSESSMENT OF AIRWAY PATHOPHYSIOLOGY C91. NEW CONCEPTS IN AIRWAYS INFLAMMATION C92. ALI/ARDS: OUTCOMES AND PREDICTORS OF FAILURE C93. HOST DEFENSES AGAINST LUNG INFECTIONS: ADVANCES AND MECHANISTIC INSIGHTS C94. VIRAL INFECTIONS IN CHILDHOOD RESPIRATORY DISEASE C95. PULMONARY ARTERIAL HYPERTENSION: THE IDEAS KEEP COMING C96. LUNG TUMORIGENESIS: INSIGHTS FROM ANIMAL MODELS C97. TGF BETA IN CHRONIC AIRWAY DISEASE: MECHANISM AND CONSEQUENCES C101. VIRAL PATHOGENESIS AND IMMUNITY C102. INFLAMMATION IN THE LUNG -- MEASURES IN EXHALED BREATH AND EFFECTS OF CIGARETTE SMOKE C103. EDUCATING PROVIDERS AND ASSESSING QUALITY OF CARE IN PULMONARY, CRITICAL CARE, AND SLEEP MEDICINE C104. ETHICS IN THE INTENSIVE CARE UNIT C105. NANOMATERIALS: LITTLE PARTICLES, BIG IMPACT C106. EPIDEMIOLOGY OF MYCOBACTERIAL DISEASE C107. PREVALENCE AND REGULATION OF EPITHELIAL MESENCHYMAL TRANSITION C108. SLEEP-DISORDERED BREATHING: OUTCOMES C109. SLEEP DISORDERED BREATHING: CARDIOVASCULAR, RESPIRATORY AND METABOLIC COMPLICATIONS Wednesday, May 20 D13. COPD EXACERBATION -- MECHANISM AND MANAGEMENT D14. TO BE OR NOT TO BE: CELL FATE AND PULMONARY VASCULAR DISEASE D15. NEW DATA REGARDING LUNG FUNCTION MEASUREMENT IN CHILDHOOD D16. OUTCOMES IN PULMONARY REHABILITATION D17. FIBROBLASTS, PROGENITOR CELLS, AND MODELS OF INTERSTITIAL FIBROSIS THAT REVEAL MECHANISMS OF DISEASE D18. NOVEL MOUSE MODELS OF DEVELOPMENT AND DISEASE FOR 2009 D19. UPPER AIRWAY: STATE-OF-THE-ART 2009 D21. GENETICS OF AIRWAY DISEASES II D22. MODULATORS OF INFLAMMATORY PATHWAYS IN AIRWAY DISEASE D23. ICU OUTCOMES D24. CARDIO-PULMONARY INTERACTION IN ICU D25. THE ROLE OF DIET, FAT, AND BODY MASS INDEX IN RESPIRATORY DISEASE D26. PNEUMOCYSTIS PNEUMONIA: UPDATES TO DETECTION, DEFENSES AND LUNG DAMAGE D27. THE PULMONARY VASCULATURE IN ACUTE LUNG INJURY D28. IMAGING OBSTRUCTIVE LUNG DISEASES I D29. LUNG REMODELING: NEW CHALLENGES AND PROMISES D30. THE ROLE OF INFLAMMATION IN CHRONIC INTERSTITIAL LUNG DISEASE D31. NEW INSIGHTS INTO INFLAMMATION AND ACUTE LUNG INJURY D32. AIRWAY INFLAMMATION: UPPER AIRWAY STUDIES AND MEASURES IN EXHALED AIR AND CONDENSATES D33. ASTHMA THERAPEUTICS -- STUDIES IN ANIMAL MODELS D34. HOST RESPONSE AND PATHOGENESIS OF INFECTIOUS AND INFLAMMATORY LUNG INJURY (TLRs AND LPs) D35. CLINICAL ISSUES IN COUGH D36. TOPICS IN BRONCHOSCOPY AND INTERVENTIONAL PULMONOLOGY D37. ENDOBRONCHIAL ULTRASOUND D38. PEDIATRIC CRITICAL CARE D39. RISK FACTORS IN THE ICU D40. UNDERSTANDING INHALATIONAL DISASTERS D41. SMOKING HEALTH EFFECTS D42. OUTCOMES FROM OCCUPATIONAL FIBERS AND DUSTS D43. HOST DEFENSE AGAINST MYCOBACTERIA D44. DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION D45. FUNGAL RESPIRATORY TRACT INFECTIONS D46. TREATMENT OF RESPIRATORY INFECTIONS D47. NEONATAL AND RARE LUNG DISEASES D48. PEDIATRIC RESPIRATORY INFECTIONS D49. GENOTYPES AND PHENOTYPES IN PH D50. MODELING STRUCTURE-FUNCTION RELATIONSHIPS D51. PATHOPHYSIOLOGY OF THE HYPERRESPONSIVE AIRWAY II D52. COUGH, DYSPNEA AND AIRWAY RECEPTORS D53. LUNG AND CHEST WALL MECHANICS D91. CURRENT CONCEPTS IN ALLERGIC AND INFLAMMATORY DENDRITIC CELL ACTIVATION D92. MECHANISMS OF IMMUNE ACTIVATION AND REGULATION D93. NON-PULMONARY PROBLEMS IN THE ICU D94. DIESEL EXHAUST AROUND THE WORLD: IMPLICATIONS FOR RESPIRATORY AND CARDIOVASCULAR HEALTH D95. UPDATE ON SEVERE COMMUNITY ACQUIRED PNEUMONIA: GUIDELINES, BIOMARKERS & STEROIDS D96. BUILDING A FIREWALL: ENDOTHELIAL BARRIER DYSFUNCTION D97. MEDIATORS OF SKELETAL MUSCLE INJURY AND REPAIR D98. SMOOTH MUSCLE CONTRACTION REVEALS ITS SECRETS D101. NEW ASPECTS OF INTERVENTIONAL PULMONOLOGY/BRONCHOSCOPY D102. CHRONIC OBSTRUCTIVE PULMONARY DISEASE PHARMACOTHERAPY D103. IMAGING OBSTRUCTIVE LUNG DISEASES II D104. EPIDEMIOLOGY OF PEDIATRIC RESPIRATORY DISEASES D105. PULMONARY VASOREACTIVITY D106. SURFACTANT AND COLLECTINS STRUCTURE AND FUNCTION: INSIGHTS INTO DISEASE MECHANISMS D107. MECHANISMS OF MUCUS PRODUCTION DURING INFLAMMATION AND INFECTION D108. INFLAMMATORY MEDIATORS: OLD AND NEW PLAYERS D109. SLEEP DISORDERED BREATHING: DEVELOPMENTAL ASPECTS, FROM BENCH TO BEDSIDE HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol. Copyright © 2009 American Thoracic Society